Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy Type
2.4. Snippet by Drug Type
2.5. Snippet by Target Antigen
2.6. Snippet by Application
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Incidence of Hematological Cancers
3.1.1.2. Growing Demand for Personalized Therapies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Costs of Therapy
3.1.2.2. Stringent Regulatory Framework
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Rising Number of Clinical Studies
3.1.3.2. XX
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest-selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. North America Regulatory and Reimbursement Landscape
4.6. Porter’s Five Force Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. CAR-T cell therapies Market, By Therapy Type
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
5.1.2. Market Attractiveness Index, By Therapy Type
5.2. Autologous CAR-T Cell Therapy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Allogeneic CAR-T Cell Therapy
6. CAR-T cell therapies Market, By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Abecma*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Breyanzi
6.4. Carvykti
6.5. Tecartus
6.6. Kymriah
6.7. Yescarta
7. CAR-T cell therapies Market, By Target Antigen
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
7.1.2. Market Attractiveness Index, By Target Antigen
7.2. CD19*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. BCMA (B-cell maturation antigen)
7.4. CD20
7.5. CD22
7.6. CD30
7.7. Others
8. CAR-T cell therapies Market, By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Acute Lymphoblastic Leukemia (ALL)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Non-Hodgkin Lymphoma
8.4. Chronic Lymphocytic Leukemia
8.5. Multiple Myeloma (MM)
8.6. Follicular Lymphoma
8.7. Others
9. Competitive Landscape and Market Positioning
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. Company Profiles
Established Players
10.1. Gilead Sciences, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Bristol Myers Squibb Company
10.3. Johnson & Johnson Services, Inc.
10.4. Novartis AG
Emerging Players
10.5. Takara Bio Inc
LIST NOT EXHAUSTIVE
11. Assumption and Research Methodology
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. Appendix
12.1. About Us and Services
12.2. Contact Us